Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.58 |
| ▸ | ACHE | P22303 | 3/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.56 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13969558 | 0.87 | HPGD (0.59) | HPGDTDP1HDAC8HSP90AA1HSP90AB1 | |
| SCHEMBL14093042 | 0.85 | HDAC8 (0.56) | HPGDTDP1HDAC8ACHEHSP90AA1 | |
| SCHEMBL4245460 | 0.85 | OPRM1 (0.64) | HPGDTDP1LMNAALDH1A1TSHR | |
| SCHEMBL7406512 | 0.84 | HPGD (0.79) | HPGDTDP1HSP90AA1HSP90AB1LMNA | |
| SCHEMBL278402 | 0.81 | ACHE (0.59) | HDAC8ACHEALDH1A1 | |
| SCHEMBL4927438 | 0.80 | HPGD (0.55) | HPGDTDP1HDAC8ACHEHSP90AA1 | |
| SCHEMBL12305535 | 0.80 | ACHE (0.53) | HDAC8ACHEMEN1KMT2A | |
| SCHEMBL11515014 | 0.79 | MLYCD (0.61) | HPGDHSP90AA1HSP90AB1LMNARECQL | |
| SCHEMBL92134 | 0.78 | HPGD (0.56) | HPGDTDP1HSP90AA1HSP90AB1LMNA | |
| SCHEMBL15417212 | 0.78 | HSP90AA1 (0.77) | HPGDTDP1HSP90AA1HSP90AB1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150166500-A1 | Compounds and Methods for Catalytic Directed ortho Substitution of Aromatic Amides and Esters | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2015-06-18 | — | — | US | disclosed |
| US-20120302752-A1 | Compounds and Methods for Catalytic Directed ortho Substitution of Aromatic Amides and Esters | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2012-11-29 | — | — | US | disclosed |
| US-8034933-B2 | graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2011-10-11 | — | — | US | disclosed |
| US-20090005375-A1 | ACETYL COENZYME A CARBOXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-01 | — | — | US | disclosed |
| US-20090005375-A1 | ACETYL COENZYME A CARBOXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-01 | — | — | US | disclosed |
| US-7442703-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442703-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080214575-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-09-04 | — | — | US | disclosed |
| US-7384948-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166500-A1 | Compounds and Methods for Catalytic Directed ortho Substitution of Aromatic Amides and Esters | DDC, AOC2, AOC3 | HPGD 2168/4885TDP1 2179/4885HDAC8 694/4885 |
| US-20120302752-A1 | Compounds and Methods for Catalytic Directed ortho Substitution of Aromatic Amides and Esters | DDC, AOC2, AOC3 | HPGD 2168/4885TDP1 2179/4885HDAC8 694/4885 |
| US-20090005375-A1 | ACETYL COENZYME A CARBOXYLASE INHIBITORS | ACACA, ACACB, ACAT1 | HPGD 705/4885TDP1 3696/4885HDAC8 1159/4885 |
| US-20080214575-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | CCR5, CCR10, CXCR3 | HPGD 4337/4885TDP1 3414/4885HDAC8 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.